Laryngeal Allograft Transplantation
Launched by MAYO CLINIC · Aug 30, 2017
Trial Information
Current as of July 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Patients with severe laryngeal or laryngotracheal incompetence without other reconstructive options will be considered for cadaveric laryngotracheal transplantation. Data will be collected from 10 patients and will include length of hospital stay, short-term complications, long-term complications, hospital readmission, return trips to the operating room (OR), rejection episodes and severity, swallowing function, ability to have tracheotomy tube decannulated, voice parameters, pulmonary function, development of anti-donor antibodies, and quality of life scores.
Gender
ALL
Eligibility criteria
- • Potential subjects for this study include patients with severe laryngeal dysfunction or a previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is defined as the loss of normal laryngeal function resulting in significant dysphonia, dysphagia, or dyspnea.
- Inclusion Criteria:
- • Ages 18 years and older
- • Male or Female
- * One of the following:
- • Severe laryngeal dysfunction as described above
- • Laryngeal stenosis
- • 5 years or longer s/p definitive management for head and neck cancer
- • Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression
- • Low-grade chondrosarcoma requiring total laryngectomy
- • Ability to obtain informed consent from the patient
- Exclusion Criteria:
- • Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation
- • General medical status
- • Pregnancy
- • Any systemic disease which would alter life expectancy
- • Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer
- • Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion)
- • Obesity (Body Mass Index \>29 - 30)(Exceptional cases will be considered on a case by case basis)
- • Cachexia (BMI\<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance \< 50 ml/min.)
- • Significant hepatic dysfunction
- • Significant kidney damage
- • Unmanageable infections
- • Unable to participate in preoperative exercise training
- • Unable to be weaned to equal or less than 10 mg/day of steroids
- • Untreatable cardiac disease
- • Active neuromuscular disease
- • History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux
- • Patients with active connective tissue diseases (exceptions to be considered in a case by case basis)
- • Patients unable to achieve \> 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis)
- • Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis)
- • Multiple co-morbidities that would make transplantation prohibitively risky
- • Psychosocial parameters
- • Severe mental retardation, psychosis, depression or organic brain syndrome
- • Uncontrolled diabetes mellitus. Once HbA1C \< 7, reevaluate for candidacy.
- • Active substance use within 6 months
- • Active smoking within 6 months
- • Active alcoholism within 6 months
- • Inability to comply with transplant-related management and medical follow-up
- • Any other circumstances that deem the candidate high risk from a psychosocial perspective
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Scottsdale, Arizona, United States
Phoenix, Arizona, United States
Patients applied
Trial Officials
David G Lott, MD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials